You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Antibody titers in sera of mice immunized with various doses of FI-MCMV with or without adjuvant by i.p. injection and viral loads in mouse organs after lethal viral challenge a

From: An adjuvanted inactivated murine cytomegalovirus (MCMV) vaccine induces potent and long-term protective immunity against a lethal challenge with virulent MCMV

Immunogen FI-MCMV ELISA titer (2n) of IgG antibodyb Spleen virus titers (log10PFU/ml) Salivary gland virus titers (log10PFU/ml)
Dosage (μg) Immunization once Immunization twice
Adjuvant-free 0.25 3.33 ± 0.58 5.67 ± 0.52 5.16 ± 0.22 Not donef
+ Chitosan   5.83 ± 1.17c 9.83 ± 1.17c 5.12 ± 0.28e Not done
+ Alum   6.67 ± 1.63c 11.17 ± 0.98c 5.06 ± 0.21e Not done
+ MF59   7.50 ± 1.52c 12.83 ± 1.47c,d 4.06 ± 0.62c,d,e 4.76 ± 0.48
Adjuvant-free 1 5.33 ± 0.58 9.17 ± 0.98 5.03 ± 0.40e Not done
+ Chitosan   6.67 ± 1.15 12.67 ± 1.03c 4.83 ± 0.12e 5.46 ± 0.57
+ Alum   7.83 ± 0.98c 14.00 ± 0.63c 4.31 ± 0.83e 5.12 ± 0.91
+ MF59   11.33 ± 0.82c,d 15.33 ± 1.03c,d 3.45 ± 0.56c,e 4.34 ± 0.42
Adjuvant-free 4 8.67 ± 0.82 11.67 ± 1.03 4.85 ± 0.21e 5.70 ± 0.38
+ Chitosan   10.50 ± 0.55c 14.83 ± 1.17c 3.95 ± 0.48c,e 4.57 ± 0.74c
+ Alum   11.00 ± 0.89c 15.17 ± 0.41c 3.61 ± 0.66c,e 4.10 ± 0.27c
+ MF59   12.17 ± 0.75c 17.00 ± 1.10c,d 2.08 ± 0.81c,d,e 2.31 ± 0.43c,d
Chitosan only - Undetected Undetected 5.76 ± 0.29 Not done
Alum only   Undetected Undetected 5.83 ± 0.38 Not done
MF59 only   Undetected Undetected 5.74 ± 0.18 Not done
Mock   Undetected Undetected 5.61 ± 0.36 Not done
PBS   - - 5.94 ± 0.25 Not done
  1. aThe mice were immunized by i.p. injection twice (3 weeks apart) with various doses of vaccine (0.25, 1, or 4 μg) with or without adjuvant (MF59, alum, or chitosan). Serum samples from immunized mice were obtained 3 weeks after the first and second immunization, respectively. Mice were challenged with a lethal dose of SG-MCMV 3 weeks after the boost. Spleen virus titers 5 days later and salivary gland virus titers 3 weeks after the challenge were measured. Results are expressed as means ± standard deviation of tested mice in each group.
  2. bSerum samples were diluted by two-fold serial dilutions and “n” represents the dilution factor.
  3. cSignificant difference (p < 0.05), compared with the corresponding adjuvant-free subjects.
  4. dSignificant difference (p < 0.05), compared with the corresponding alum adjuvant subjects.
  5. eSignificant difference (p < 0.05), compared with control subjects.
  6. fViral titer measurement was not performed because of the mouse death before the day 21 post-infection.